Golcadomide
- Generic Name
- Golcadomide
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30FN5O5
- CAS Number
- 2379572-34-4
- Unique Ingredient Identifier
- 29HLR8Z5BR
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 400
- Registration Number
- NCT06911502
- Locations
- 🇺🇸
Local Institution - 0214, Tampa, Florida, United States
🇵🇱Local Institution - 0189, Łódź, Łódzkie, Poland
🇺🇸Local Institution - 0008, Jacksonville, Florida, United States
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Conditions
- Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: LeukapheresisProcedure: Positron Emission Tomography
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT06834373
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States
Golcadomide and Nivolumab in Patients with Non-Hodgkin Lymphoma with Refractory Disease After Chimeric Antigen T-cell Therapy
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Natalie Galanina
- Target Recruit Count
- 30
- Registration Number
- NCT06767956
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT06535399
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Local Institution - 0004, Chandler, Arizona, United States
🇺🇸Local Institution - 0005, Orlando, Florida, United States
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇺🇸Local Institution - 0036, New York, New York, United States
🇺🇸Utah Cancer Specialists, Salt Lake City, Utah, United States
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT06363630
- Locations
- 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸Local Institution - 0001, Lenexa, Kansas, United States
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
- Conditions
- Refractory Transformed B-cell Non-Hodgkin LymphomaDiffuse Large B-cell Lymphoma RefractoryRefractory Primary Mediastinal Large B-Cell LymphomaRefractory High Grade B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 65
- Registration Number
- NCT06271057
- Locations
- 🇫🇷
Hopital Henri Mondor, Créteil, France
🇫🇷Chu Dijon Bourgogne, Dijon, France
🇫🇷Chu de Grenoble, La Tronche, France
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma-RecurrentHigh Grade B-Cell Lymphoma-RecurrentPrimary Mediastinal Large B-Cell Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RecurrentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RefractoryDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RefractoryFollicular Lymphoma-Refractory
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Nathan Denlinger
- Target Recruit Count
- 18
- Registration Number
- NCT06209619
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06108232
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.